IN8bio to Present at the TD Cowen 45th Annual Health Care Conference
IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company specializing in gamma-delta T cell therapies, has announced its upcoming participation in the TD Cowen 45th Annual Health Care Conference. William Ho, CEO and co-founder, will deliver a presentation on Monday, March 3, 2025, at 10:30 a.m. ET.
Interested parties can access both the live webcast and replay of the presentation through the 'Events and Presentations' section within the News & Presentations area on IN8bio's investor relations website at https://investors.in8bio.com.
IN8bio (Nasdaq: INAB), un'azienda biofarmaceutica in fase clinica specializzata in terapie con cellule T gamma-delta, ha annunciato la sua prossima partecipazione alla 45ª Conferenza Annuale sulla Salute di TD Cowen. William Ho, CEO e co-fondatore, presenterà il suo intervento lunedì 3 marzo 2025, alle 10:30 ET.
Le parti interessate possono accedere sia alla diretta streaming che alla registrazione della presentazione attraverso la sezione 'Eventi e Presentazioni' nell'area News & Presentations del sito web delle relazioni con gli investitori di IN8bio all'indirizzo https://investors.in8bio.com.
IN8bio (Nasdaq: INAB), una compañía biofarmacéutica en etapa clínica especializada en terapias con células T gamma-delta, ha anunciado su próxima participación en la 45ª Conferencia Anual de Salud de TD Cowen. William Ho, CEO y cofundador, ofrecerá una presentación el lunes 3 de marzo de 2025, a las 10:30 a.m. ET.
Las partes interesadas pueden acceder tanto a la transmisión en vivo como a la repetición de la presentación a través de la sección 'Eventos y Presentaciones' en el área de Noticias y Presentaciones del sitio web de relaciones con inversores de IN8bio en https://investors.in8bio.com.
IN8bio (Nasdaq: INAB), 감마-델타 T 세포 치료를 전문으로 하는 임상 단계의 생명공학 회사가 TD Cowen 제45회 연례 건강 관리 회의에 참여할 예정이라고 발표했습니다. William Ho, CEO이자 공동 창립자는 2025년 3월 3일 월요일 오전 10시 30분 ET에 발표를 진행할 예정입니다.
관심 있는 분들은 IN8bio의 투자자 관계 웹사이트의 뉴스 및 발표 섹션 내 '이벤트 및 발표'를 통해 생중계와 발표 재생 모두에 접근할 수 있습니다: https://investors.in8bio.com.
IN8bio (Nasdaq: INAB), une entreprise biopharmaceutique en phase clinique spécialisée dans les thérapies par cellules T gamma-delta, a annoncé sa prochaine participation à la 45e Conférence Annuelle sur la Santé de TD Cowen. William Ho, PDG et co-fondateur, présentera une communication le lundi 3 mars 2025, à 10h30 ET.
Les parties intéressées peuvent accéder à la fois à la diffusion en direct et à la rediffusion de la présentation via la section 'Événements et Présentations' dans la zone Actualités et Présentations du site web des relations investisseurs d'IN8bio à l'adresse suivante : https://investors.in8bio.com.
IN8bio (Nasdaq: INAB), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Gamma-Delta-T-Zelltherapien spezialisiert hat, hat seine bevorstehende Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen angekündigt. William Ho, CEO und Mitgründer, wird am Montag, den 3. März 2025, um 10:30 Uhr ET eine Präsentation halten.
Interessierte Parteien können sowohl auf das Live-Streaming als auch auf die Wiederholung der Präsentation über den Bereich 'Veranstaltungen und Präsentationen' im Bereich Nachrichten und Präsentationen auf der Investoren-Website von IN8bio unter https://investors.in8bio.com zugreifen.
- None.
- None.
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will be presenting at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 10:30 a.m. ET.
A live webcast and replay will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website at https://investors.in8bio.com.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program INB-400 is in a Phase 2 trial in GBM. Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit www.IN8bio.com.
Investor & Corporate Contact
Glenn Schulman, PharmD, MPH
IN8bio, Inc.
203.494.7411
gdschulman@IN8bio.com
Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com
FAQ
When is IN8bio (INAB) presenting at the TD Cowen Health Care Conference 2025?
How can investors watch IN8bio's (INAB) TD Cowen conference presentation?
What type of therapies does IN8bio (INAB) specialize in?
Who will represent IN8bio (INAB) at the TD Cowen Healthcare Conference?
